The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Is adjuvant oxaliplatin (Ox) overutilized in colon cancer (CC): 408 cases from the practices of 102 oncologists.
Kathryn Ziel
No relevant relationships to disclose
Axel Grothey
Research Funding - Bayer; Daiichi Sankyo; Genentech
Alan Paul Venook
Consultant or Advisory Role - Sanofi
Research Funding - Bayer; Genentech; Genomic Health; GlaxoSmithKline; Onyx
Atif Mahmoud Hussein
No relevant relationships to disclose
Jonathan Moss
No relevant relationships to disclose
Neil Love
No relevant relationships to disclose